Herantis Pharma Announces Successful rhCDNF Results With Nanoform Technology
Press Release Herantis Pharma Plc 9 September 2021 at 08:00 a.m. Eastern European Summer Time Herantis Pharma Plc (“Herantis”), focusing on disease modifying therapies for debilitating neurodegenerative diseases based on the natural body protein CDNF (Cerebral Dopamine Neurotrophic Factor), today announced positive initial results from the project with Nanoform Finland Plc, an innovative nanoparticle medicine enabling company. Herantis has two promising assets being developed in tandem for Parkinson’s Disease – recombinant human CDNF (rhCDNF) a biological protein to be